je.st
news
Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial...
2013-01-12 04:25:40| Biotech - Topix.net
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer .
Tags: results
trial
phase
announce
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||